Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for Celiac Disease Gluten Challenge
NCT02929316Phase 2Terminated
- Sponsor
- AGA Clinical Research Associates
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in celiac disease, sponsored by AGA Clinical Research Associates. Started Jun 2018; status: terminated.
02
Drugs
vedolizumab
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT02929316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929316.